(3R,4S)-1-benzoyl-4-phenyl-3-triethylsilyloxyazetidin-2-one

We are (3R,4S)-1-benzoyl-4-phenyl-3-triethylsilyloxyazetidin-2-one CAS:149249-91-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:(3R,4S)-1-benzoyl-4-phenyl-3-triethylsilyloxyazetidin-2-one
CAS.NO:149249-91-2
Synonyms:(3R,4S)-1-benzoyl-4-phenyl-3-triethylsilyloxyazetidin-2-one
1-benzoyl-4-phenyl-3-triethylsilanyloxy-azetidin-2-one
N-benzoyl-3-triethylsilyloxy-4-phenylazetidin-2-one
 
Physical and Chemical Properties:
Density 1.1±0.1 g/cm3
Boiling Point 467.2±55.0 °C at 760 mmHg
Molecular Formula C22H27NO3Si
Molecular Weight 381.540
Flash Point 236.4±31.5 °C
Vapour Pressure 0.0±1.2 mmHg at 25°C
Index of Refraction 1.567
 
Specification:
Appearance:White to light yellow powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Cabazitaxel(CAS:183133-96-2) and Paclitaxel(CAS:33069-62-4).

(3R,4S)-1-benzoyl-4-phenyl-3-triethylsilyloxyazetidin-2-one


Related News: Genzyme Pharmaceuticals develops and manufactures chemically synthesized pharmaceutical materials and technologies for the global pharmaceutical industry and focuses on lipids, peptides, carbohydrates, oligonucleotides, and custom small molecules.Carbamato de bencilo (1-ciano-1-metiletil) CAS:100134-82-5 Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL.147-85-3 Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL.29490-19-5 In the first round of nationwide implement of the program, in September, multinationals including Sanofi and Eli Lilly managed to cut some prices low enough to levels close to those offered by local generic makers.In the first round of nationwide implement of the program, in September, multinationals including Sanofi and Eli Lilly managed to cut some prices low enough to levels close to those offered by local generic makers.

Related Products
Product Name
3-AMINO-2,6-DIFLUOROBENZOIC ACID View Details
3-Methyl-4-methylthiophenol View Details
N-Ethyl-2,3-dioxopiperazine View Details
4-Bromo-2-chloropyridine manufacturer 4-methylaminophenol sulfate manufacturer 5,6-Dibromopyridine-3-carboxylic acid manufacturer 1-Hydroxypyrene manufacturer 2,4-Dichloro-3,5-dinitrobenzotrifluoride manufacturer